|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM028160703 |
| 003 |
DE-627 |
| 005 |
20231221105127.0 |
| 007 |
tu |
| 008 |
231221s1988 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0094.xml
|
| 035 |
|
|
|a (DE-627)NLM028160703
|
| 035 |
|
|
|a (NLM)2834746
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Silva Cruz, A
|e verfasserin
|4 aut
|
| 245 |
1 |
3 |
|a An open assessment of three different treatment regimens of itraconazole for the management of vaginal candidosis
|
| 264 |
|
1 |
|c 1988
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 27.05.1988
|
| 500 |
|
|
|a Date Revised 21.11.2013
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a An assessment was carried out in 59 women with proven vaginal candidosis to compare the efficacy and tolerance of itraconazole used in three different treatment regimens. Patients were allocated at random to receive a single oral dose of 200 mg itraconazole for 1, 2 or 3 days. They were reassessed 1 week and 4 weeks after treatment for remission of clinical signs and symptoms and repeat mycological investigations. All three regimens yielded successful clinical results, global evaluation at 4 weeks showing complete remission in 100% (5/5), 81.5% (25/27) and 92.3% (24/26) of patients, respectively. One patient (on 2-day treatment) required alternative treatment before the 4-week assessment. Minor gastric side-effects were reported by a few patients on the 2-day and 3-day treatment regimens; these resolved spontaneously
|
| 650 |
|
4 |
|a Clinical Trial
|
| 650 |
|
4 |
|a Comparative Study
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Randomized Controlled Trial
|
| 650 |
|
7 |
|a Antifungal Agents
|2 NLM
|
| 650 |
|
7 |
|a Itraconazole
|2 NLM
|
| 650 |
|
7 |
|a 304NUG5GF4
|2 NLM
|
| 650 |
|
7 |
|a Ketoconazole
|2 NLM
|
| 650 |
|
7 |
|a R9400W927I
|2 NLM
|
| 700 |
1 |
|
|a Andrade, L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Oliveira, J E
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sobral, J L
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC)
|d 1995
|g 5(1988), 3 vom: 05., Seite 189-92
|w (DE-627)NLM023961570
|
| 773 |
1 |
8 |
|g volume:5
|g year:1988
|g number:3
|g day:05
|g pages:189-92
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_39
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_121
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 5
|j 1988
|e 3
|b 05
|h 189-92
|